About kymera therapeutics inc - KYMR
Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of human diseases through the development of innovative, highly differentiated medicines. It focuses on discovering and developing novel small-molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s natural protein degradation system. The company leverages targeted protein degradation (TPD) to develop medicines that address critical health challenges and have the potential to significantly improve patients lives. Its pipeline emphasizes oral small-molecule degraders, offering a new generation of convenient and highly effective therapies. The company was founded by Bruce Lee Booth and Nello Mainolfi on September 29, 2015 and is headquartered in Watertown, MA.
KYMR At a Glance
Kymera Therapeutics, Inc.
500 North Beacon Street
Watertown, Massachusetts 02472
| Phone | 1-857-285-5300 | Revenue | 47.07M | |
| Industry | Biotechnology | Net Income | -223,858,000.00 | |
| Sector | Health Technology | Employees | 188 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
KYMR Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 64.136 |
| Price to Book Ratio | 3.124 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -10.50 |
| Enterprise Value to Sales | 55.618 |
| Total Debt to Enterprise Value | 0.034 |
KYMR Efficiency
| Revenue/Employee | 250,382.979 |
| Income Per Employee | -1,190,734.043 |
| Receivables Turnover | 49.706 |
| Total Asset Turnover | 0.061 |
KYMR Liquidity
| Current Ratio | 7.53 |
| Quick Ratio | 7.53 |
| Cash Ratio | 7.212 |
KYMR Profitability
| Gross Margin | 84.337 |
| Operating Margin | -545.356 |
| Pretax Margin | -475.565 |
| Net Margin | -475.565 |
| Return on Assets | -28.814 |
| Return on Equity | -36.382 |
| Return on Total Capital | -24.243 |
| Return on Invested Capital | -32.36 |
KYMR Capital Structure
| Total Debt to Total Equity | 10.503 |
| Total Debt to Total Capital | 9.504 |
| Total Debt to Total Assets | 8.973 |
| Long-Term Debt to Equity | 8.933 |
| Long-Term Debt to Total Capital | 8.084 |